| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | Iodine131-ILym-1, Lym-1, Oncolym |
| Clonality | |
| Expression System | |
| Form | Liquid |
| Host | |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Storage | |
| Target | |
| UniProt # |
Product Overview
Oncolym (HM813016) is a research-grade recombinant antibody targeting HLA class II histocompatibility antigen. Produced in mammalian cells with native-like glycosylation. Highlights- ●Research Grade — For PK/PD studies, assay development, and ADA research.
- ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Specifications
| Host Species | Mouse |
|---|---|
| Species Reactivity | Human |
| Clonality | Monoclonal |
| Isotype | IgG2a, nd |
| Target | HLA class II histocompatibility antigen, DRB1 beta chain, Human leukocyte antigen DRB1, HLA-DRB1 |
| Purification | Protein A/G purified from cell culture supernatant. |
| Purity | >95% purity as determined by SDS-PAGE. |
| Form | Liquid |
| Storage Buffer | 0.01M PBS, pH 7.4. |
| Expression System | Mammalian Cells |
| UniProt | P01911 |
Validated Applications
| Application |
|---|
| ELISA |
| Flow Cytometry |
| Functional Assay |
| In Vivo Studies |
Scientific Background
HLA class II histocompatibility antigen, DRB1 beta chain (HLA-DR10) is a ~29 kDa protein. A beta chain of antigen-presenting major histocompatibility complex class II (MHCII) molecule. In complex with the alpha chain HLA-DRA, displays antigenic peptides on professional antigen presenting cells (APCs) for recognition by alpha-beta T cell receptor (TCR) on HLA-DRB1-restricted CD4-positive T cells. T
Reactivity
This antibody shows reactivity with Human.
Safety & Handling
Customization & Add-ons: Can't find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
1. Shams, H. et al. (2004) Journal of immunology (Baltimore, Md. : 1950) 173, 1966-77. PMID: 15265931
2. Schulze zur Wiesch, J. et al. (2005) Journal of immunology (Baltimore, Md. : 1950) 175, 3603-13. PMID: 16148104
3. Kwok, WW. et al. (2012) Journal of immunology (Baltimore, Md. : 1950) 188, 2537-44. PMID: 22327072
4. Muehling, LM. et al. (2016) Journal of immunology (Baltimore, Md. : 1950) 197, 3214-3224. PMID: 27591323
5. Galperin, M. et al. (2018) Science immunology 3. PMID: 29884618
6. Abelin, JG. et al. (2019) Immunity 51, 766-779.e17. PMID: 31495665
7. Topalian, SL. et al. (1996) The Journal of experimental medicine 183, 1965-71. PMID: 8642306
8. Stern, LJ. et al. (1994) Nature 368, 215-21. PMID: 8145819
9. Schmid, D. et al. (2007) Immunity 26, 79-92. PMID: 17182262
